甲状腺癌
端粒酶逆转录酶
医学
甲状腺癌
端粒酶
癌症研究
相伴的
甲状腺
突变
转移
癌症
内科学
肿瘤科
生物
基因
遗传学
出处
期刊:Endocrine Journal
[Japan Endocrine Society]
日期:2020-06-29
卷期号:67 (6): 577-584
被引量:61
标识
DOI:10.1507/endocrj.ej20-0063
摘要
Given the long-term survival of most patients with thyroid cancer, it is very important to distinguish patients who need aggressive treatment from those who do not. Conventional clinicopathological prognostic parameters could not completely predict the final outcome of each patient. Recently, molecular marker-based risk stratification of thyroid cancer has been proposed to better estimate the cancer risk. Although BRAF mutation has drawn much attention based on its high prevalence, its association with recurrence or mortality is not clear. Recently, telomerase reverse transcriptase (TERT) promoter mutation has been identified in thyroid cancer. It increases telomerase activity, which allows cancer cells to immortalize. It was found in 10 to 20% of differentiated thyroid carcinoma and 40% of dedifferentiated thyroid carcinoma. It is highly prevalent in old age, large tumor, aggressive histology, advanced stages, and distant metastasis. It is associated with increased recurrence and mortality. Concomitant BRAF and TERT promoter mutations worsen the survival rate. Inclusion of TERT promoter mutation analysis with conventional clinicopathological evaluation can lead to better prognostication and management for individual patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI